首页 > 最新文献

Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

英文 中文
Abdominal obesity (Waist Circumference/Waist Circumference-to-Height Ratio) as a new vital sign in Asian Indians: The most dangerous fat we rarely measure 腹部肥胖(腰围/腰围与身高比)是亚洲印度人新的生命体征:我们很少测量最危险的脂肪。
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-03-01 Epub Date: 2026-02-18 DOI: 10.1016/j.dsx.2026.103389
Amerta Ghosh , Anoop Misra
{"title":"Abdominal obesity (Waist Circumference/Waist Circumference-to-Height Ratio) as a new vital sign in Asian Indians: The most dangerous fat we rarely measure","authors":"Amerta Ghosh , Anoop Misra","doi":"10.1016/j.dsx.2026.103389","DOIUrl":"10.1016/j.dsx.2026.103389","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 3","pages":"Article 103389"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147358487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of early life exposure to active play and movement on health and wellbeing across the lifespan: A narrative review of RCTs from 2020-2025 早期生活接触积极游戏和运动对整个生命周期健康和福祉的影响:2020-2025年随机对照试验的叙述性回顾
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-03-01 Epub Date: 2026-03-05 DOI: 10.1016/j.dsx.2026.103399
Andrew P. Hills , Fadiah Alkhattabi , Reem Alahmed , Saleh Ali Alessy , Sisitha Jayasinghe , Sadeem Aldarwesh , Rowaedh A. Bawaked , Lama Abdulla , Sawsan Albalawi , Afaf Alsagheir , Ghadi Alaskar , Severin Rakic , Predrag Zivotic , Volkan Cetinkaya , Saleh A. Alqahtani

Introduction/background

Competence in fundamental movement skills (FMS) is associated with higher physical activity levels across childhood and adolescence, influencing lifelong movement behaviours. Despite these benefits, most children globally fail to meet recommended physical activity levels from an early age and are increasingly affected by unhealthy body composition and chronic conditions such as obesity and type 2 diabetes (T2D). This article synthesises current evidence on early-life movement behaviours and interventions promoting physical activity during the first 2000 days, a critical developmental period shaping long-term health.

Materials and methods

A comprehensive search of peer-reviewed randomized controlled trials (RCTs) published between 2020 and 2025 in Medline and Scopus identified studies examining physical activity, motor skill development, and related health outcomes in children aged 0-5 years. Findings were organized into five themes: (1) movement behaviours and early health; (2) historical development of guidelines; (3) global consensus and gaps; (4) early-years interventions; and (5) emerging implications.

Results

Eighteen studies met inclusion criteria. Evidence highlighted the importance of physical activity, adequate rest, and limited sedentary behaviour for early development. Most studies focused on preschoolers, with fewer addressing infants and toddlers. Interventions were largely from high-income contexts and varied in design and measurement tools. Integrating physical literacy showed promise.

Discussion

Early movement experiences shape body composition and chronic disease risk. Focusing on the first and next 1000 days may foster lifelong healthy habits. Future work should enhance equity, diversity, and measurement consistency in interventions.
基本运动技能(FMS)能力与儿童期和青春期较高的身体活动水平相关,影响终生的运动行为。尽管有这些好处,但全球大多数儿童从小就未能达到建议的身体活动水平,并且越来越多地受到不健康的身体构成和肥胖和2型糖尿病等慢性疾病的影响。这篇文章综合了目前关于生命早期运动行为和干预措施的证据,这些干预措施促进了头2000天的身体活动,这是塑造长期健康的关键发育时期。材料和方法对发表在Medline和Scopus上的同行评审随机对照试验(rct)进行了全面检索,确定了研究0-5岁儿童身体活动、运动技能发展和相关健康结果的研究。研究结果分为五个主题:(1)运动行为与早期健康;(2)指南的历史发展;(3)全球共识与差距;(4)早期干预;(5)新出现的影响。结果18项研究符合纳入标准。证据强调了身体活动、充足的休息和有限的久坐行为对早期发育的重要性。大多数研究集中在学龄前儿童身上,针对婴幼儿的研究较少。干预措施主要来自高收入背景,设计和测量工具各不相同。整合体育素养显示出了希望。早期运动经历塑造身体成分和慢性疾病风险。专注于最初的1000天和接下来的1000天,可以培养终身健康的习惯。未来的工作应加强干预措施的公平性、多样性和测量一致性。
{"title":"Impact of early life exposure to active play and movement on health and wellbeing across the lifespan: A narrative review of RCTs from 2020-2025","authors":"Andrew P. Hills ,&nbsp;Fadiah Alkhattabi ,&nbsp;Reem Alahmed ,&nbsp;Saleh Ali Alessy ,&nbsp;Sisitha Jayasinghe ,&nbsp;Sadeem Aldarwesh ,&nbsp;Rowaedh A. Bawaked ,&nbsp;Lama Abdulla ,&nbsp;Sawsan Albalawi ,&nbsp;Afaf Alsagheir ,&nbsp;Ghadi Alaskar ,&nbsp;Severin Rakic ,&nbsp;Predrag Zivotic ,&nbsp;Volkan Cetinkaya ,&nbsp;Saleh A. Alqahtani","doi":"10.1016/j.dsx.2026.103399","DOIUrl":"10.1016/j.dsx.2026.103399","url":null,"abstract":"<div><h3>Introduction/background</h3><div>Competence in fundamental movement skills (FMS) is associated with higher physical activity levels across childhood and adolescence, influencing lifelong movement behaviours. Despite these benefits, most children globally fail to meet recommended physical activity levels from an early age and are increasingly affected by unhealthy body composition and chronic conditions such as obesity and type 2 diabetes (T2D). This article synthesises current evidence on early-life movement behaviours and interventions promoting physical activity during the first 2000 days, a critical developmental period shaping long-term health.</div></div><div><h3>Materials and methods</h3><div>A comprehensive search of peer-reviewed randomized controlled trials (RCTs) published between 2020 and 2025 in Medline and Scopus identified studies examining physical activity, motor skill development, and related health outcomes in children aged 0-5 years. Findings were organized into five themes: (1) movement behaviours and early health; (2) historical development of guidelines; (3) global consensus and gaps; (4) early-years interventions; and (5) emerging implications.</div></div><div><h3>Results</h3><div>Eighteen studies met inclusion criteria. Evidence highlighted the importance of physical activity, adequate rest, and limited sedentary behaviour for early development. Most studies focused on preschoolers, with fewer addressing infants and toddlers. Interventions were largely from high-income contexts and varied in design and measurement tools. Integrating physical literacy showed promise.</div></div><div><h3>Discussion</h3><div>Early movement experiences shape body composition and chronic disease risk. Focusing on the first and next 1000 days may foster lifelong healthy habits. Future work should enhance equity, diversity, and measurement consistency in interventions.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 3","pages":"Article 103399"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147451133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of alpha lipoic acid supplementation on biochemical, clinical, and inflammatory parameters in patients with diabetic polyneuropathy: A systematic review and meta-analysis 补充α硫辛酸对糖尿病多发神经病变患者生化、临床和炎症参数的影响:一项系统综述和荟萃分析
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-01 Epub Date: 2026-01-23 DOI: 10.1016/j.dsx.2026.103374
Ayline Vergara Salinas , Trinidad Meneses Caroca , Fernanda Peña Santibáñez , Javiera Rojo González , Michelle López-Chaparro , Marisol Barahona-Vásquez , Jessica Paola Loaiza-Giraldo , Consuelo Gómez-Valdovinos , Juan José Valenzuela-Fuenzalida , Pablo Nova-Baeza , Mathias Orellana-Donoso , Alejandro Bruna-Mejias , Gloria Cifuentes-Suazo , Gustavo Oyanedel-Amaro , Juan Sanchis-Gimeno , Guinevere Granite , Felipe Araya-Quintanilla

Introduction

In this article, we perform a systematic review and meta-analysis evaluating the effects of alpha-lipoic acid (ALA) supplementation on biochemical, clinical, inflammatory, and functional parameters in patients with diabetic polyneuropathy or diabetic peripheral neuropathy (DPN). A total of 15 articles were included, of which 12 were analyzed for outcomes. DPN is a chronic complication of Diabetes Mellitus (DM) characterized by symptoms, such as pain, sensory disturbances, and reduced quality of life. Currently, there is no definitive cure. Management focuses on controlling blood glucose and alleviating symptoms through pharmacological and non-pharmacological therapies. The aim of this study is to analyze the evidence regarding the efficacy of alpha-lipoic acid (ALA) supplementation in the management of DPN.

Results

A systematic search across multiple databases was conducted using keywords, such as “diabetes mellitus,” “diabetes mellitus type I,” “diabetes mellitus type II,” “alpha-lipoic acid,” and “ALA supplementation.” A total of 15 studies met the inclusion criteria. Of the 23 outcomes analyzed, 19 showed significant differences in favor of alpha-lipoic acid (ALA) supplementation at different doses versus a placebo or other treatments. Notable improvements were observed in Total Symptom Score (TSS) paresthesia (SMD = −1.04; 95 % CI = −1.24 to −0.84; p < 0.00001), TSS numbness (SMD = −0.23; 95 % CI = −0.44 to −0.01; p = 0.04), and the Hamburg Pain Adjective List (HPAL) (SMD = −1.00; 95 % CI = −1.15 to −0.85; p < 0.00001), among others. These improvements were particularly evident for symptoms, such as paresthesia, numbness, and burning sensations, especially at a dose of 600 mg/day. In contrast, four of the outcomes HbA1c, nitric oxide levels, sural sensory nerve action potential, and peroneal motor nerve conduction velocity showed no significant changes.

Conclusion

The evidence suggests that ALA, especially at 600 mg/day, is a safe and potentially effective adjunct therapy for symptom management in DPN, although its impact on nerve conduction and long-term glycemic control remains inconclusive.
在这篇文章中,我们进行了一项系统回顾和荟萃分析,评估了补充α -硫辛酸(ALA)对糖尿病多发性神经病变或糖尿病周围神经病变(DPN)患者的生化、临床、炎症和功能参数的影响。共纳入15篇文章,其中12篇对结果进行分析。DPN是糖尿病(DM)的一种慢性并发症,以疼痛、感觉障碍和生活质量下降等症状为特征。目前,尚无确切的治疗方法。治疗的重点是通过药物和非药物治疗控制血糖和减轻症状。本研究的目的是分析关于α -硫辛酸(ALA)补充治疗DPN疗效的证据。结果以“diabetes mellitus”、“diabetes mellitus type I”、“diabetes mellitus type II”、“α -硫辛酸”、“ALA supplement”等关键词对多个数据库进行了系统检索。共有15项研究符合纳入标准。在分析的23个结果中,有19个显示不同剂量的α -硫辛酸(ALA)补充剂与安慰剂或其他治疗相比有显著差异。在总症状评分(TSS)感觉异常(SMD = - 1.04; 95% CI = - 1.24至- 0.84;p < 0.00001)、TSS麻木(SMD = - 0.23; 95% CI = - 0.44至- 0.01;p = 0.04)和汉堡疼痛形容词表(HPAL) (SMD = - 1.00; 95% CI = - 1.15至- 0.85;p < 0.00001)等方面均有显著改善。这些改善对感觉异常、麻木和烧灼感等症状尤其明显,特别是在600毫克/天的剂量下。相比之下,糖化血红蛋白、一氧化氮水平、腓肠感觉神经动作电位、腓运动神经传导速度等4项指标无明显变化。结论尽管ALA对神经传导和长期血糖控制的影响尚不明确,但证据表明ALA,特别是600 mg/天,是一种安全且潜在有效的DPN症状管理辅助治疗。
{"title":"Effectiveness of alpha lipoic acid supplementation on biochemical, clinical, and inflammatory parameters in patients with diabetic polyneuropathy: A systematic review and meta-analysis","authors":"Ayline Vergara Salinas ,&nbsp;Trinidad Meneses Caroca ,&nbsp;Fernanda Peña Santibáñez ,&nbsp;Javiera Rojo González ,&nbsp;Michelle López-Chaparro ,&nbsp;Marisol Barahona-Vásquez ,&nbsp;Jessica Paola Loaiza-Giraldo ,&nbsp;Consuelo Gómez-Valdovinos ,&nbsp;Juan José Valenzuela-Fuenzalida ,&nbsp;Pablo Nova-Baeza ,&nbsp;Mathias Orellana-Donoso ,&nbsp;Alejandro Bruna-Mejias ,&nbsp;Gloria Cifuentes-Suazo ,&nbsp;Gustavo Oyanedel-Amaro ,&nbsp;Juan Sanchis-Gimeno ,&nbsp;Guinevere Granite ,&nbsp;Felipe Araya-Quintanilla","doi":"10.1016/j.dsx.2026.103374","DOIUrl":"10.1016/j.dsx.2026.103374","url":null,"abstract":"<div><h3>Introduction</h3><div>In this article, we perform a systematic review and meta-analysis evaluating the effects of alpha-lipoic acid (ALA) supplementation on biochemical, clinical, inflammatory, and functional parameters in patients with diabetic polyneuropathy or diabetic peripheral neuropathy (DPN). A total of 15 articles were included, of which 12 were analyzed for outcomes. DPN is a chronic complication of Diabetes Mellitus (DM) characterized by symptoms, such as pain, sensory disturbances, and reduced quality of life. Currently, there is no definitive cure. Management focuses on controlling blood glucose and alleviating symptoms through pharmacological and non-pharmacological therapies. The aim of this study is to analyze the evidence regarding the efficacy of alpha-lipoic acid (ALA) supplementation in the management of DPN.</div></div><div><h3>Results</h3><div>A systematic search across multiple databases was conducted using keywords, such as “diabetes mellitus,” “diabetes mellitus type I,” “diabetes mellitus type II,” “alpha-lipoic acid,” and “ALA supplementation.” A total of 15 studies met the inclusion criteria. Of the 23 outcomes analyzed, 19 showed significant differences in favor of alpha-lipoic acid (ALA) supplementation at different doses versus a placebo or other treatments. Notable improvements were observed in Total Symptom Score (TSS) paresthesia (SMD = −1.04; 95 % CI = −1.24 to −0.84; p &lt; 0.00001), TSS numbness (SMD = −0.23; 95 % CI = −0.44 to −0.01; p = 0.04), and the Hamburg Pain Adjective List (HPAL) (SMD = −1.00; 95 % CI = −1.15 to −0.85; p &lt; 0.00001), among others. These improvements were particularly evident for symptoms, such as paresthesia, numbness, and burning sensations, especially at a dose of 600 mg/day. In contrast, four of the outcomes HbA1c, nitric oxide levels, sural sensory nerve action potential, and peroneal motor nerve conduction velocity showed no significant changes.</div></div><div><h3>Conclusion</h3><div>The evidence suggests that ALA, especially at 600 mg/day, is a safe and potentially effective adjunct therapy for symptom management in DPN, although its impact on nerve conduction and long-term glycemic control remains inconclusive.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103374"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146081425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of fibrosis-4 and NAFLD fibrosis score for screening liver fibrosis in Indian individuals with type 2 diabetes: a prospective cross-sectional study 纤维化-4和NAFLD纤维化评分在印度2型糖尿病患者肝纤维化筛查中的表现:一项前瞻性横断面研究
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-01 DOI: 10.1016/j.dsx.2026.103380
Narendra Singh Choudhary , Mohammad Shafi Kuchay , Swapnil Dhampalwar , Kunwar Ashish Singh , Manish Kumar Singh , Gargi Singh , Neeraj Saraf , Ajay Duseja

Background

Blood-based non-invasive tests (NITs) in patients with T2DM/MASLD help in assessing the stage of hepatic fibrosis, but there is sparse data in the Indian population.

Methods

Fibrosis-4 (FIB-4) and NAFLD fibrosis score (NFS) were calculated for all individuals with T2DM with MASLD and compared to liver stiffness measurement (LSM) values obtained by vibration-controlled transient elastography (VCTE) with cut-offs of ≥9.7 kPa (rule-in cut-off for advanced fibrosis) and <6 kPa (as a rule-out cut-off for significant fibrosis).

Results

The prospective study included 789 patients (238 females) with T2DM and MASLD, aged 53.3 ± 10.3 years. The LSM values were ≥9.7 in 102 (12.9%). Results for the whole group were as follows: The optimal rule-in cut-off for FIB-4 was 1.68 (AUROC 0.69, 95% CI 0.637–0.746, sensitivity 64.7%, specificity 65.2%). The optimal rule-in cut-off of NFS for advanced fibrosis was −0.389 (AUROC 0.619, 95% CI 0.560 to 0.678, sensitivity 61.8%, specificity 57.4%). Rule-out cut-offs also had poor AUROCs (0.586 for FIB-4 and 0.570 for NFS). The diagnostic accuracy of the earlier suggested rule-in (for advanced fibrosis) cut-offs of FIB-4 (>2.67) was 81.3% (sensitivity 22.1%, specificity 92.2%). The diagnostic accuracy of NFS (>0.675) for advanced fibrosis was 79.4% (sensitivity 21.3% and specificity 90.1%). The diagnostic accuracy of the rule-out cut-offs was 52.7% for FIB-4 (at value < 1.3) and 53.8% for NFS (at value < -1.455).

Conclusion

The performance of FIB-4 and NFS to predict or rule out advanced fibrosis was poor in Indian patients with type 2 diabetes mellitus and MASLD.
背景:T2DM/MASLD患者的血液无创检查(NITs)有助于评估肝纤维化的分期,但在印度人群中缺乏相关数据。方法:计算所有T2DM合并MASLD患者的纤维化-4 (FIB-4)和NAFLD纤维化评分(NFS),并与振动控制瞬时弹性成像(VCTE)获得的肝刚度测量(LSM)值进行比较,临界值≥9.7 kPa(晚期纤维化的规则临界值)。结果:前瞻性研究包括789例T2DM合并MASLD患者(238例女性),年龄53.3±10.3岁。LSM值≥9.7的102例(12.9%)。整个组的结果如下:FIB-4的最佳规则截止值为1.68 (AUROC 0.69, 95% CI 0.637-0.746,敏感性64.7%,特异性65.2%)。NFS诊断晚期纤维化的最佳标准截止值为-0.389 (AUROC为0.619,95% CI为0.560 ~ 0.678,敏感性61.8%,特异性57.4%)。排除截止点的auroc也很差(FIB-4为0.586,NFS为0.570)。早期建议的(晚期纤维化)FIB-4(>2.67)阈值的诊断准确性为81.3%(敏感性22.1%,特异性92.2%)。NFS(>0.675)对晚期纤维化的诊断准确率为79.4%(敏感性21.3%,特异性90.1%)。结论:FIB-4和NFS在印度2型糖尿病和MASLD患者中预测或排除晚期纤维化的性能较差。
{"title":"Performance of fibrosis-4 and NAFLD fibrosis score for screening liver fibrosis in Indian individuals with type 2 diabetes: a prospective cross-sectional study","authors":"Narendra Singh Choudhary ,&nbsp;Mohammad Shafi Kuchay ,&nbsp;Swapnil Dhampalwar ,&nbsp;Kunwar Ashish Singh ,&nbsp;Manish Kumar Singh ,&nbsp;Gargi Singh ,&nbsp;Neeraj Saraf ,&nbsp;Ajay Duseja","doi":"10.1016/j.dsx.2026.103380","DOIUrl":"10.1016/j.dsx.2026.103380","url":null,"abstract":"<div><h3>Background</h3><div>Blood-based non-invasive tests (NITs) in patients with T2DM/MASLD help in assessing the stage of hepatic fibrosis, but there is sparse data in the Indian population.</div></div><div><h3>Methods</h3><div>Fibrosis-4 (FIB-4) and NAFLD fibrosis score (NFS) were calculated for all individuals with T2DM with MASLD and compared to liver stiffness measurement (LSM) values obtained by vibration-controlled transient elastography (VCTE) with cut-offs of ≥9.7 kPa (rule-in cut-off for advanced fibrosis) and &lt;6 kPa (as a rule-out cut-off for significant fibrosis).</div></div><div><h3>Results</h3><div>The prospective study included 789 patients (238 females) with T2DM and MASLD, aged 53.3 ± 10.3 years. The LSM values were ≥9.7 in 102 (12.9%). Results for the whole group were as follows: The optimal rule-in cut-off for FIB-4 was 1.68 (AUROC 0.69, 95% CI 0.637–0.746, sensitivity 64.7%, specificity 65.2%). The optimal rule-in cut-off of NFS for advanced fibrosis was −0.389 (AUROC 0.619, 95% CI 0.560 to 0.678, sensitivity 61.8%, specificity 57.4%). Rule-out cut-offs also had poor AUROCs (0.586 for FIB-4 and 0.570 for NFS). The diagnostic accuracy of the earlier suggested rule-in (for advanced fibrosis) cut-offs of FIB-4 (&gt;2.67) was 81.3% (sensitivity 22.1%, specificity 92.2%). The diagnostic accuracy of NFS (&gt;0.675) for advanced fibrosis was 79.4% (sensitivity 21.3% and specificity 90.1%). The diagnostic accuracy of the rule-out cut-offs was 52.7% for FIB-4 (at value &lt; 1.3) and 53.8% for NFS (at value &lt; -1.455).</div></div><div><h3>Conclusion</h3><div>The performance of FIB-4 and NFS to predict or rule out advanced fibrosis was poor in Indian patients with type 2 diabetes mellitus and MASLD.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103380"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global assessment of insulin and oral hypoglycaemic agent accessibility and affordability: A cross-sectional survey of international diabetes federation member countries 胰岛素和口服降糖药的可及性和可负担性的全球评估:国际糖尿病联合会成员国的横断面调查。
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-01 Epub Date: 2026-01-31 DOI: 10.1016/j.dsx.2026.103378
Bishwajit Bhowmik , Tasnima Siddiquee , Nayla Cdv. Moreira , Amit Gupta , Banshi Saboo , A.K.A. Khan , Sameer Pathan , Phil Riley , Abhimanyu S. Chauhan

Aims

To examine global stakeholder perspectives on the availability, affordability, and access barriers to insulin and oral hypoglycaemic agents (OHAs), based on a cross-sectional survey of International Diabetes Federation (IDF) member associations.

Methods

A mixed-methods online survey was conducted among designated informants from 86 IDF member associations across 131 responses. The questionnaire covered medicine availability, reimbursement mechanisms, affordability, and access constraints. Quantitative data were analysed descriptively, and open-ended responses were thematically analysed. In cases of multiple responses from the same country, all were included to capture diverse perspectives.

Results

Insulin analogues were reported as available in 68.8% of settings, with full reimbursement in 63.5%. Biguanides and sulfonylureas were the most available OHAs. Major access barriers included high out-of-pocket costs, limited insurance coverage, supply disruptions, and insufficient patient education. Regional representation was uneven, with over-representation from South and Central America and under-representation from South-East Asia; thus, subgroup comparisons should be interpreted with caution.

Conclusions

Substantial perceived disparities in access to diabetes medicines persist across countries, particularly in low- and lower-middle-income settings. These findings reinforce the urgent need for improved financing, strengthened supply chains, and integrated patient-centred strategies. This study contributes to the global evidence base by providing a contemporary, policy-relevant snapshot of diabetes medicine access challenges in 2024–2025, supporting national and international efforts to close equity gaps.
目的:根据国际糖尿病联合会(IDF)成员协会的横断面调查,研究全球利益相关者对胰岛素和口服降糖药(OHAs)的可得性、可负担性和获取障碍的看法。方法:对来自86个IDF成员协会的指定告密者进行了一项混合方法的在线调查,涉及131个回答。调查问卷涵盖药品可得性、报销机制、可负担性和获取限制。定量数据进行描述性分析,开放式回答进行主题分析。在同一国家有多个答复的情况下,所有答复都包括在内,以反映不同的观点。结果:胰岛素类似物在68.8%的情况下可获得,63.5%的情况下全额报销。双胍类化合物和磺脲类化合物是最有效的oha。获得治疗的主要障碍包括高昂的自付费用、有限的保险覆盖范围、供应中断和患者教育不足。区域代表性不均衡,南美洲和中美洲的代表性过高,而东南亚的代表性不足;因此,亚组比较应谨慎解释。结论:各国在糖尿病药物可及性方面存在显著差异,特别是在低收入和中低收入环境中。这些发现强调了改善融资、加强供应链和以患者为中心的综合战略的迫切需要。本研究通过提供2024-2025年糖尿病药物可及性挑战的当代、与政策相关的快照,为全球证据基础做出贡献,支持国家和国际努力缩小公平差距。
{"title":"Global assessment of insulin and oral hypoglycaemic agent accessibility and affordability: A cross-sectional survey of international diabetes federation member countries","authors":"Bishwajit Bhowmik ,&nbsp;Tasnima Siddiquee ,&nbsp;Nayla Cdv. Moreira ,&nbsp;Amit Gupta ,&nbsp;Banshi Saboo ,&nbsp;A.K.A. Khan ,&nbsp;Sameer Pathan ,&nbsp;Phil Riley ,&nbsp;Abhimanyu S. Chauhan","doi":"10.1016/j.dsx.2026.103378","DOIUrl":"10.1016/j.dsx.2026.103378","url":null,"abstract":"<div><h3>Aims</h3><div>To examine global stakeholder perspectives on the availability, affordability, and access barriers to insulin and oral hypoglycaemic agents (OHAs), based on a cross-sectional survey of International Diabetes Federation (IDF) member associations.</div></div><div><h3>Methods</h3><div>A mixed-methods online survey was conducted among designated informants from 86 IDF member associations across 131 responses. The questionnaire covered medicine availability, reimbursement mechanisms, affordability, and access constraints. Quantitative data were analysed descriptively, and open-ended responses were thematically analysed. In cases of multiple responses from the same country, all were included to capture diverse perspectives.</div></div><div><h3>Results</h3><div>Insulin analogues were reported as available in 68.8% of settings, with full reimbursement in 63.5%. Biguanides and sulfonylureas were the most available OHAs. Major access barriers included high out-of-pocket costs, limited insurance coverage, supply disruptions, and insufficient patient education. Regional representation was uneven, with over-representation from South and Central America and under-representation from South-East Asia; thus, subgroup comparisons should be interpreted with caution.</div></div><div><h3>Conclusions</h3><div>Substantial perceived disparities in access to diabetes medicines persist across countries, particularly in low- and lower-middle-income settings. These findings reinforce the urgent need for improved financing, strengthened supply chains, and integrated patient-centred strategies. This study contributes to the global evidence base by providing a contemporary, policy-relevant snapshot of diabetes medicine access challenges in 2024–2025, supporting national and international efforts to close equity gaps.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103378"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights of the current issue 当前问题的重点
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-01 Epub Date: 2026-02-20 DOI: 10.1016/j.dsx.2026.103390
Ningjian Wang , Anoop Misra
{"title":"Highlights of the current issue","authors":"Ningjian Wang ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2026.103390","DOIUrl":"10.1016/j.dsx.2026.103390","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103390"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147422264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the performance of non-invasive risk models to predict incident type 2 diabetes in a Swedish population – Västerbotten Intervention Programme 瑞典人群中预测2型糖尿病事件的非侵入性风险模型的性能评估- Västerbotten干预方案。
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-01 Epub Date: 2026-01-29 DOI: 10.1016/j.dsx.2026.103379
Melony Fortuin-de Smidt , Olov Rolandsson , Simon J. Griffin , Patrik Wennberg

Aim

We assessed the performance of non-invasive risk prediction models to predict 10-year incident type 2 diabetes in a large Swedish cohort.

Methods

Using the Västerbotten Intervention Programme (VIP) cohort, which includes serial oral glucose tolerance tests (OGTTs), we assessed discrimination (concordance (c)-statistic) and calibration (expected-to-observed probability ratio, integrated calibration index, calibration slope and plots) before and after recalibration in twelve non-invasive models. Incident diabetes cases were determined by an OGTT at a 10-year follow-up visit or through previously validated register-based cases.

Results

Among 91708 VIP participants, the 10-year diabetes incidence was 2.8 %. Most models had acceptable discrimination (c-statistic ≥0.70 and < 0.80). Discrimination was better in women and persons <50 years old. Eight models overestimated and four models underestimated mean absolute risk. Recalibration improved miscalibration in all models. Overall, the Framingham Personal and QDScore models’ predictions were most accurate but the Framingham model included more easily obtainable variables. Most models overestimated risk in older people while no consistent pattern was observed across sexes.

Conclusion

All models required recalibration to improve prediction accuracy. The Framingham personal model is recommended for risk predictions and will be the easiest to implement.
目的:我们评估了非侵入性风险预测模型的性能,以预测一个大型瑞典队列的10年2型糖尿病事件。方法:采用Västerbotten干预计划(VIP)队列,包括系列口服糖耐量试验(ogtt),我们评估了12种无创模型重新校准前后的鉴别(一致性(c)统计量)和校准(期望与观测概率比、综合校准指数、校准斜率和图)。在10年的随访中通过OGTT或通过先前验证的基于登记册的病例来确定偶发糖尿病病例。结果:91708名VIP参与者中,10年糖尿病发病率为2.8%。大多数模型具有可接受的判别性(c-statistic≥0.70)。结论:所有模型都需要重新校准以提高预测精度。弗雷明汉个人模型被推荐用于风险预测,并且是最容易实施的。
{"title":"Assessment of the performance of non-invasive risk models to predict incident type 2 diabetes in a Swedish population – Västerbotten Intervention Programme","authors":"Melony Fortuin-de Smidt ,&nbsp;Olov Rolandsson ,&nbsp;Simon J. Griffin ,&nbsp;Patrik Wennberg","doi":"10.1016/j.dsx.2026.103379","DOIUrl":"10.1016/j.dsx.2026.103379","url":null,"abstract":"<div><h3>Aim</h3><div>We assessed the performance of non-invasive risk prediction models to predict 10-year incident type 2 diabetes in a large Swedish cohort.</div></div><div><h3>Methods</h3><div>Using the Västerbotten Intervention Programme (VIP) cohort, which includes serial oral glucose tolerance tests (OGTTs), we assessed discrimination (concordance (c)-statistic) and calibration (expected-to-observed probability ratio, integrated calibration index, calibration slope and plots) before and after recalibration in twelve non-invasive models. Incident diabetes cases were determined by an OGTT at a 10-year follow-up visit or through previously validated register-based cases.</div></div><div><h3>Results</h3><div>Among 91708 VIP participants, the 10-year diabetes incidence was 2.8 %. Most models had acceptable discrimination (c-statistic ≥0.70 and &lt; 0.80). Discrimination was better in women and persons &lt;50 years old. Eight models overestimated and four models underestimated mean absolute risk. Recalibration improved miscalibration in all models. Overall, the Framingham Personal and QDScore models’ predictions were most accurate but the Framingham model included more easily obtainable variables. Most models overestimated risk in older people while no consistent pattern was observed across sexes.</div></div><div><h3>Conclusion</h3><div>All models required recalibration to improve prediction accuracy. The Framingham personal model is recommended for risk predictions and will be the easiest to implement.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103379"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The prevalence of cardiometabolic and renal long-term conditions in individuals with type 2 diabetes mellitus: a global umbrella review 2型糖尿病患者心脏代谢和肾脏长期疾病的患病率:一项全球综述
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-01 Epub Date: 2026-02-03 DOI: 10.1016/j.dsx.2026.103381
Sarah Hassen , Cameron Razieh , Lauren O'Mahoney , Thomas J. Wilkinson , Aleksandra Gawlik-Lipinski , Shukrat O. Salisu-Olatunji , Elizabeth Hickman , Monica Kundu , Kamlesh Khunti , Clare L. Gillies

Background and aims

There is a high prevalence of long-term conditions (LTCs) among people with type 2 diabetes (T2D). This umbrella review synthesises and collates the existing evidence.

Methods

This review was registered in PROSPERO (CRD42024490470) and follows the Joanna Briggs Institute guidelines (JBI) for umbrella reviews. Comprehensive searches of Ovid Medline, Ovid Embase, Cochrane, and CINAHL databases were conducted. Systematic reviews of observational studies on cardiometabolic and renal LTCs in T2D were included. Quality was assessed using the JBI Critical Appraisal Checklist for systematic reviews, and study results were narratively synthesised.

Results

Out of 10,721 records, 20 systematic reviews (15 with meta-analyses) were included, comprising 675 primary studies. The most commonly reported cardiometabolic condition in T2D was cardiovascular disease, with a pooled prevalence ranging from 13·0% (95% CI: 11·0,15·0) to 46·0% (39·0, 54·0), followed by heart failure with the highest pooled prevalence reported as 25·0% (21·0, 28·0). For renal conditions in T2D, the overall pooled prevalence for nephropathy ranged from 4·2% (3·2, 5·3) to 38·0% (14·0, 63·0), while chronic kidney disease reported prevalence ranged from 18·2% (15·1, 21·4) to 35·5% (25·9, 45·5). The prevalence of these conditions varied by sex and income status, with higher rates observed in males and low-income and middle-income countries.

Conclusion

This review highlights the significant prevalence of cardiometabolic and renal LTCs in T2D, highlighting the need for targeted and holistic management approaches to address these comorbidities effectively.
背景和目的:在2型糖尿病(T2D)患者中,长期疾病(LTCs)的患病率很高。这一综述综合和整理了现有的证据。方法:本综述在PROSPERO杂志注册(CRD42024490470),遵循乔安娜布里格斯研究所指南(JBI)进行总结性综述。全面检索Ovid Medline、Ovid Embase、Cochrane和CINAHL数据库。系统回顾了t2dm中心脏代谢和肾脏LTCs的观察性研究。使用JBI关键评估清单进行系统评价,并对研究结果进行叙述性综合。结果:在10,721项记录中,包括20项系统评价(15项荟萃分析),包括675项主要研究。t2dm中最常见的心脏代谢疾病是心血管疾病,合并患病率从13.0% (95% CI: 11.0, 15.0)到46.0%(39.0,54.0),其次是心力衰竭,合并患病率最高,为25.0%(21.0,28.0)。对于T2D的肾脏疾病,肾病的总总患病率从4.2%(3.2,5.3)到38.0%(14.0,63.0)不等,而慢性肾脏疾病的患病率从18.2%(15.1,21.4)到35.5%(25.9,45.5)不等。这些疾病的患病率因性别和收入状况而异,男性和低收入和中等收入国家的发病率较高。结论:本综述强调了T2D中心脏代谢和肾脏LTCs的显著患病率,强调了有针对性和全面的管理方法来有效解决这些合并症的必要性。
{"title":"The prevalence of cardiometabolic and renal long-term conditions in individuals with type 2 diabetes mellitus: a global umbrella review","authors":"Sarah Hassen ,&nbsp;Cameron Razieh ,&nbsp;Lauren O'Mahoney ,&nbsp;Thomas J. Wilkinson ,&nbsp;Aleksandra Gawlik-Lipinski ,&nbsp;Shukrat O. Salisu-Olatunji ,&nbsp;Elizabeth Hickman ,&nbsp;Monica Kundu ,&nbsp;Kamlesh Khunti ,&nbsp;Clare L. Gillies","doi":"10.1016/j.dsx.2026.103381","DOIUrl":"10.1016/j.dsx.2026.103381","url":null,"abstract":"<div><h3>Background and aims</h3><div>There is a high prevalence of long-term conditions (LTCs) among people with type 2 diabetes (T2D). This umbrella review synthesises and collates the existing evidence.</div></div><div><h3>Methods</h3><div>This review was registered in PROSPERO (CRD42024490470) and follows the Joanna Briggs Institute guidelines (JBI) for umbrella reviews. Comprehensive searches of Ovid Medline, Ovid Embase, Cochrane, and CINAHL databases were conducted. Systematic reviews of observational studies on cardiometabolic and renal LTCs in T2D were included. Quality was assessed using the JBI Critical Appraisal Checklist for systematic reviews, and study results were narratively synthesised.</div></div><div><h3>Results</h3><div>Out of 10,721 records, 20 systematic reviews (15 with meta-analyses) were included, comprising 675 primary studies. The most commonly reported cardiometabolic condition in T2D was cardiovascular disease, with a pooled prevalence ranging from 13·0% (95% CI: 11·0,15·0) to 46·0% (39·0, 54·0), followed by heart failure with the highest pooled prevalence reported as 25·0% (21·0, 28·0). For renal conditions in T2D, the overall pooled prevalence for nephropathy ranged from 4·2% (3·2, 5·3) to 38·0% (14·0, 63·0), while chronic kidney disease reported prevalence ranged from 18·2% (15·1, 21·4) to 35·5% (25·9, 45·5). The prevalence of these conditions varied by sex and income status, with higher rates observed in males and low-income and middle-income countries.</div></div><div><h3>Conclusion</h3><div>This review highlights the significant prevalence of cardiometabolic and renal LTCs in T2D, highlighting the need for targeted and holistic management approaches to address these comorbidities effectively.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103381"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of glucose monitoring devices on relationships with food and eating behaviour for people with type 2 diabetes mellitus: A review of the literature 血糖监测设备对2型糖尿病患者与食物和饮食行为关系的影响:文献综述
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-01 Epub Date: 2026-02-13 DOI: 10.1016/j.dsx.2026.103376
S. Mackie , T. Wallace , J. Heath

Background

There is limited understanding of the impact of glucose monitoring technologies on relationships with food and eating behaviours for those with type 2 diabetes mellitus (T2DM).

Aims

With previous reviews focused on T2DM treatment burden and self-management, this review aims to enhance understanding of the impact of flash or continuous glucose monitoring (FGM/CGM) on users’ eating behaviours and relationships with food as this can inform important recommendations for CGM use amongst those with T2DM.

Method

A systematic search was conducted across four databases: Scopus, Medline, CINAHL and PubMed, from October-November 2024, following PRISMA guidelines. Studies were quality appraised and qualitative data was synthesized using thematic synthesis.

Findings

Thirteen studies met inclusion criteria and their findings were included in the synthesis. The review revealed that F/CGM enhanced participants’ nutritional awareness, supported personalised dietary experimentation, and fostered intentional eating behaviours. However, data overload and emotional burden were also reported, with some users experiencing restrictive or distressing impacts on their relationship with food. These insights inform practical recommendations for CGM implementation with those with T2DM.

Conclusion

Further research should aim to identify factors that contribute to successful adaptation to CGM and explore the long-term effects of CGM use on food relationships.
背景:对于2型糖尿病(T2DM)患者的血糖监测技术与食物和饮食行为之间的关系的影响了解有限。目的:由于以往的综述侧重于T2DM治疗负担和自我管理,本综述旨在加强对快速或连续血糖监测(FGM/CGM)对使用者饮食行为和与食物关系的影响的理解,因为这可以为T2DM患者使用CGM提供重要建议。方法:根据PRISMA指南,对Scopus、Medline、CINAHL和PubMed四个数据库进行系统检索,检索时间为2024年10 - 11月。对研究进行了质量评价,并利用专题综合对定性数据进行了综合。结果:13项研究符合纳入标准,他们的研究结果被纳入综合。综述显示,F/CGM增强了参与者的营养意识,支持个性化饮食实验,并培养了有意识的饮食行为。然而,数据过载和情绪负担也被报道,一些用户在与食物的关系上受到限制或痛苦的影响。这些见解为T2DM患者实施CGM提供了实用建议。结论:进一步的研究应旨在确定成功适应CGM的因素,并探索CGM使用对食物关系的长期影响。
{"title":"The impact of glucose monitoring devices on relationships with food and eating behaviour for people with type 2 diabetes mellitus: A review of the literature","authors":"S. Mackie ,&nbsp;T. Wallace ,&nbsp;J. Heath","doi":"10.1016/j.dsx.2026.103376","DOIUrl":"10.1016/j.dsx.2026.103376","url":null,"abstract":"<div><h3>Background</h3><div>There is limited understanding of the impact of glucose monitoring technologies on relationships with food and eating behaviours for those with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Aims</h3><div>With previous reviews focused on T2DM treatment burden and self-management, this review aims to enhance understanding of the impact of flash or continuous glucose monitoring (FGM/CGM) on users’ eating behaviours and relationships with food as this can inform important recommendations for CGM use amongst those with T2DM.</div></div><div><h3>Method</h3><div>A systematic search was conducted across four databases: Scopus, Medline, CINAHL and PubMed, from October-November 2024, following PRISMA guidelines. Studies were quality appraised and qualitative data was synthesized using thematic synthesis.</div></div><div><h3>Findings</h3><div>Thirteen studies met inclusion criteria and their findings were included in the synthesis. The review revealed that F/CGM enhanced participants’ nutritional awareness, supported personalised dietary experimentation, and fostered intentional eating behaviours. However, data overload and emotional burden were also reported, with some users experiencing restrictive or distressing impacts on their relationship with food. These insights inform practical recommendations for CGM implementation with those with T2DM.</div></div><div><h3>Conclusion</h3><div>Further research should aim to identify factors that contribute to successful adaptation to CGM and explore the long-term effects of CGM use on food relationships.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103376"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146260554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-weight-bearing lower-limb simple resistance activities, soleus push-ups, and muscle stretching: Impact on glycemic control and metabolic–circulatory outcomes 非负重下肢简单阻力活动、比目鱼俯卧撑和肌肉拉伸:对血糖控制和代谢循环结果的影响
IF 3.4 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-01 Epub Date: 2026-01-10 DOI: 10.1016/j.dsx.2026.103375
Raju Vaishya , Abhishek Vaish , Patinharayil Gopinathan , Anoop Misra

Objective

To review the role of lower-body skeletal muscle non-weight-bearing simple resistance activities (SRAs), soleus push-ups (SPUs), and stretching exercises (SEs) in improving glycemic control and metabolic/circulatory outcomes in those individuals who cannot do weight-bearing aerobic exercises due to musculoskeletal, cardiorespiratory and other reasons.

Research design and methods

We conducted a narrative review of randomized controlled trials, prospective cohorts, and pilot interventions identified through searches of PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, EBSCO, and ScienceDirect. We examined non-weight-bearing SRAs, SPUs, and SEs, focusing on pathophysiological mechanisms and clinical outcomes.

Results

Moderate lower-body strength is associated with 32–35% lower type 2 diabetes (T2D) risk (HR: 0.68, 95% CI: 0.49–0.94). Interrupting prolonged sitting with 3-min SRAs every 30 min reduces insulin response by 26%. SPUs—sustained, seated plantarflexion contractions—reduce postprandial glucose by 39–52% and insulin response by 60% during oral glucose tolerance tests. Passive SE for 40 min acutely lowered blood glucose by 24–28 mg/dL, chronically improves femoral blood flow by 30% and flow-mediated dilation by 25%. Benefits are likely mediated through AMPK-dependent GLUT4 translocation, myokine secretion, and improved endothelial function.

Conclusions

Lower-body SRAs, SPUs, and SEs are simple interventions that can be performed while seated and have the potential to significantly improve glucose regulation, insulin sensitivity, and vascular function in populations unable to engage in traditional weight-bearing aerobic exercise. Integration into clinical practice could provide cost-effective tools for the prevention and management of T2D. Finally, the effects of these exercises should be evaluated in long-term studies to determine their impact on glycaemic control and cardiovascular protection.
目的:探讨下半身骨骼肌非负重简单阻力运动(sra)、比目鱼俯卧撑(SPUs)和拉伸运动(SEs)对因肌肉骨骼、心肺等原因不能进行负重有氧运动的患者血糖控制和代谢/循环结局的改善作用。研究设计和方法:我们对通过PubMed/MEDLINE、Scopus、Web of Science、Cochrane Library、EBSCO和ScienceDirect检索到的随机对照试验、前瞻性队列和试点干预措施进行了叙述性回顾。我们检查了非负重sra、spu和se,重点关注病理生理机制和临床结果。结果:适度的下半身力量与2型糖尿病(T2D)风险降低32-35%相关(HR: 0.68, 95% CI: 0.49-0.94)。中断长时间静坐,每30分钟进行3分钟的sra,可使胰岛素反应降低26%。在口服葡萄糖耐量试验中,spus持续的坐式跖屈收缩可使餐后血糖降低39-52%,胰岛素反应降低60%。被动SE治疗40分钟,急性降低血糖24- 28mg /dL,慢性改善股血流量30%,血流介导扩张25%。益处可能通过ampk依赖性GLUT4易位、肌因子分泌和内皮功能改善介导。结论:下体sra、spu和SEs是一种简单的干预措施,可以在坐着的情况下进行,并且有可能显著改善无法进行传统负重有氧运动的人群的葡萄糖调节、胰岛素敏感性和血管功能。与临床实践相结合可以为T2D的预防和管理提供具有成本效益的工具。最后,这些运动的效果应该在长期研究中进行评估,以确定它们对血糖控制和心血管保护的影响。
{"title":"Non-weight-bearing lower-limb simple resistance activities, soleus push-ups, and muscle stretching: Impact on glycemic control and metabolic–circulatory outcomes","authors":"Raju Vaishya ,&nbsp;Abhishek Vaish ,&nbsp;Patinharayil Gopinathan ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2026.103375","DOIUrl":"10.1016/j.dsx.2026.103375","url":null,"abstract":"<div><h3>Objective</h3><div>To review the role of lower-body skeletal muscle non-weight-bearing simple resistance activities (SRAs), soleus push-ups (SPUs), and stretching exercises (SEs) in improving glycemic control and metabolic/circulatory outcomes in those individuals who cannot do weight-bearing aerobic exercises due to musculoskeletal, cardiorespiratory and other reasons.</div></div><div><h3>Research design and methods</h3><div>We conducted a narrative review of randomized controlled trials, prospective cohorts, and pilot interventions identified through searches of PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, EBSCO, and ScienceDirect. We examined non-weight-bearing SRAs, SPUs, and SEs, focusing on pathophysiological mechanisms and clinical outcomes.</div></div><div><h3>Results</h3><div>Moderate lower-body strength is associated with 32–35% lower type 2 diabetes (T2D) risk (HR: 0.68, 95% CI: 0.49–0.94). Interrupting prolonged sitting with 3-min SRAs every 30 min reduces insulin response by 26%. SPUs—sustained, seated plantarflexion contractions—reduce postprandial glucose by 39–52% and insulin response by 60% during oral glucose tolerance tests. Passive SE for 40 min acutely lowered blood glucose by 24–28 mg/dL, chronically improves femoral blood flow by 30% and flow-mediated dilation by 25%. Benefits are likely mediated through AMPK-dependent GLUT4 translocation, myokine secretion, and improved endothelial function.</div></div><div><h3>Conclusions</h3><div>Lower-body SRAs, SPUs, and SEs are simple interventions that can be performed while seated and have the potential to significantly improve glucose regulation, insulin sensitivity, and vascular function in populations unable to engage in traditional weight-bearing aerobic exercise. Integration into clinical practice could provide cost-effective tools for the prevention and management of T2D. Finally, the effects of these exercises should be evaluated in long-term studies to determine their impact on glycaemic control and cardiovascular protection.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103375"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Diabetes & Metabolic Syndrome-Clinical Research & Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1